November 22, 2020

5 min read

Opinions expressed by Entrepreneur contributors are their own.

We know the is shrinking, unemployment is up and the future of will remain digital during this seemingly endless pandemic. On top of that, we’ve just started the holiday season, which accounts for 40 percent of brands’ annual revenue.

As a expert, with experience working at L’Oréal and , and as a founder of a boutique agency, I know that consumer product brands have been planning their holiday strategy for months — photographing new value sets, fine-tuning promotions, honing hero product assortments and re-negotiating revenue targets. For them, the holiday season starts now and gradually ramps up to Cyber Week. By the time comes around, brand marketers are already planning for their spring launches.

But this holiday season won’t be as usual.

Let’s assume that

The COVID-19 pandemic is the biggest challenge the world is facing since World War-II and is an important turning point in the history of humanity, Prime Minister said at the on Saturday, as he offered India’s IT prowess for efficient functioning of the grouping.

Modi also said that “Work from Anywhere” is a new normal in the post-COVID world and suggested creation of a virtual G20 secretariat.

The prime minister also suggested developing a new global index for the post-corona world that comprises four key elements — creation of a vast talent pool, ensuring that technology reaches all segments of society, transparency in systems of governance and dealing with Mother Earth with a spirit of trusteeship.

Based on this, the G20 can lay the foundation of a new world, he said.

Saudi Arabia’s

made a strong debut on the bourses on Friday. The stock got listed at Rs 1,701 — a 13.4 per cent premium to its issue price — and ended the session at Rs 1,820, up 21 per cent over its issue price. The post-listing market capitalisation for the company stands at Rs 29,848 crore, helping it break into the top 10 valuable pharma firms in the country.

The Rs 6,480-crore IPO was one of the biggest by a pharma company in the domestic market. The price band was set at Rs 1,490-1,500 per share. The IPO comprised a fresh issue of Rs 1,250 crore and an offer for sale of Rs 5,230 crore. The firm plans to use the proceeds to fund working capital requirements.

The Fosun-promoted firm’s IPO had managed to sail through on the back of institutional